(Total Views: 751)
Posted On: 06/29/2024 5:10:33 PM
Post# of 154158
I asked on MDGL yahoo message board about the trial. Here was one poster's answer:
docj
1 day ago
Anyone know anything about a preclinical MASH study by CYDY using leronlimab alone and in combo with Resmetirom?
Reply
Share
ExPharmaGuy
6 hours ago
Yes, this has been announced.
Its a preclinical trial combining leronlimab, a CCR 5 antagonist with Res.
The odds that this will evolve into a sponsored registrational trial are very low.
This MOA alone so far has been proven ineffective in NASH and HIV/NASH
The company that is supplying LL is facing a mountain of financial and legal problems.
Their old CEO who has been indicted for fraud, pumped LL for NASH, 2 yrs ago, but the data was poor.
If this is the drug combo that MDGL wants to push forward, then something is terribly wrong.
IMO [only], its being done to placate the KOL who is running the study.
docj
1 day ago
Anyone know anything about a preclinical MASH study by CYDY using leronlimab alone and in combo with Resmetirom?
Reply
Share
ExPharmaGuy
6 hours ago
Yes, this has been announced.
Its a preclinical trial combining leronlimab, a CCR 5 antagonist with Res.
The odds that this will evolve into a sponsored registrational trial are very low.
This MOA alone so far has been proven ineffective in NASH and HIV/NASH
The company that is supplying LL is facing a mountain of financial and legal problems.
Their old CEO who has been indicted for fraud, pumped LL for NASH, 2 yrs ago, but the data was poor.
If this is the drug combo that MDGL wants to push forward, then something is terribly wrong.
IMO [only], its being done to placate the KOL who is running the study.
(12)
(2)
